President Trump signed the "Big, Beautiful Bill" into law on July 4.During the first half of 2025, the stock market was heavily influenced by new tariff policies introduced by the Trump administration. Now, a week into the second half of the year, President Donald Trump hasn't stopped introducing legislation that will further sway the direction of the capital markets.On July 4, Trump signed the "big, beautiful bill" into law. Like many pieces of legislation, the bill covers a variety of topics. But for this ...

Key Takeaways MRK faces major headwinds as Keytruda, its top seller, nears the loss of exclusivity in 2028. Gardasil sales dropped 40% in Q1 2025 due to weak China demand, despite strength in other regions. MRK expects IRA's Medicare drug pricing to impact Januvia in 2026 and Keytruda starting in 2028.Merck (MRK) is expected to face several hurdles over the next few years that could affect its long-term growth trajectory, starting with the anticipated loss of exclusivity of its blockbuster PD-L1 inhibitor ...

Barclays CEO Energy-Power Conference S E P T E M B E R 2 0 2 3 Disclaimer Forward-Looking Statements The forward-looking statements contained in this presentation are based on our current expectations and beliefs concerning future developments, as well as a number of assumptions concerning future events, and their potential effects on our business. These forward-looking statements are not guarantees of performance, and there can be no assurance that future developments affecting our business will be those t ...

Key Takeaways PFE expects steady 2025 COVID sales but anticipates major LOE losses and IRA headwinds in the future. Medicare Part D changes may cut into sales of key PFE drugs like Vyndaqel, Ibrance, Xtandi and Xeljanz. PFE trades at 7.82x forward earnings, below industry average, with EPS estimates rising for 2025 and 2026.Pfizer (PFE) is likely to encounter several headwinds in the next couple of years that can hurt its sales and profits, the first being declining sales of COVID products, Comirnaty and ...

Core Insights - Constellation Energy Corporation (CEG) is significantly benefiting from the Production Tax Credit (PTC) for nuclear energy, which provides a per-kilowatt-hour incentive for electricity generated from eligible resources [1][2][9] - The PTC, part of the Inflation Reduction Act, enhances CEG's revenues, especially during low power market prices, thereby protecting profitability and supporting the operation of nuclear plants [2][9] - CEG anticipates over 13% adjusted operating earnings growth through 2030, driven by PTC benefits, operational improvements, and planned refueling outages [3][9] Financial Performance - CEG's shares have increased by 39.4% over the past three months, outperforming the industry growth of 19.1% [8] - The Zacks Consensus Estimate indicates a 9% increase in earnings per share for 2025 and a 22.09% increase for 2026 [11] - CEG is trading at a premium with a forward 12-month price-to-earnings ratio of 29.43X compared to the industry average of 20.8X [14] Revenue Protection Mechanism - The PTC provides crucial downside protection for CEG's nuclear plants when revenues fall below $44.75/MWh, with inflation adjustments enhancing this safeguard [4][9] - CEG expects an incremental base revenue of $500 million in 2028, contingent on inflation adjustments between 2.3% and 2.6% [4] Growth Initiatives - CEG's consistent PTC earnings allow for investments in growth initiatives such as repowering wind assets, extending plant licenses, and acquiring new assets [3][5]

May 21, 2025 05:26 AM GMT Regulated Utilities | North America AGA Conference Day 3: Key Takeaways On day 3 of AGA, we hosted meetings with the following utility management teams: CNP, AEE, NJR. We highlight takeaways in this note. We highlight takeaways from day 3 of the American Gas Association (AGA) Conference below. Ameren (AEE - EW): Conversations with data centers remain highly active. The company filed its data center tariff proposal in MO last week, aiming to ensure these new large loads are neutral ...

Summary of Alnylam Pharmaceuticals (ALNY) 2025 Conference Call Company Overview - **Company**: Alnylam Pharmaceuticals (ALNY) - **Event**: Bank of America Healthcare Conference - **Date**: May 14, 2025 Key Industry Insights - **Impact of Executive Orders**: The recent executive order regarding most favored nation pricing is still developing, making it difficult to assess its implications for Alnylam. However, the company benefits from having orphan drugs in the U.S., which may exempt them from future price negotiations under the IRA [3][4] - **Tariffs**: Current tariffs do not materially impact Alnylam's guidance, as the majority of their manufacturing is done in the U.S. through contract manufacturing organizations (CMOs) [8][9] Product Launch and Market Dynamics - **Cardiomyopathy Launch**: The launch of the cardiomyopathy product is a significant focus. Initial metrics show that 50% of health systems have completed the PNT process and are on formulary within five weeks of launch, which is faster than anticipated [18][19] - **Revenue Guidance**: Alnylam has guided for TTR revenue between $1.6 billion and $1.725 billion for the year, representing a 36% growth at the midpoint [23] - **Patient Access**: Approximately 70% of patients on the drug have zero out-of-pocket costs, primarily due to Medicare fee-for-service coverage [30] Competitive Landscape - **Market Size and Segmentation**: There are about 18,000 new patients initiating therapy annually, with a significant opportunity to increase diagnosis rates, currently at a 20% diagnosis rate [48] - **First-Line vs. Second-Line Treatment**: Alnylam is focused on first-line treatment due to the progressive nature of the disease and the need for effective early intervention [49] Patient and Physician Engagement - **Patient Compliance**: Alnylam has observed good compliance rates with their injectable therapies, which may be more effective than oral alternatives in ensuring patients receive the necessary treatment [58][60] - **Physician Awareness**: There is a good level of awareness among physicians regarding Alnylam's products, but further education is needed as the company expands its prescriber base [74] Future Outlook - **Revenue Reporting**: Alnylam will not be able to report revenue separately for Ambutra PN and Ambutra Centimeters due to them being the same product under one SKU [67] - **Market Positioning**: Alnylam is uniquely positioned to capture a broad patient base, including both hereditary and wild-type patients, due to its comprehensive label [72][73] Additional Considerations - **Direct-to-Consumer (DTC) Marketing**: Alnylam is engaging in targeted DTC marketing but is not heavily investing in broad campaigns like some competitors [65] - **Value-Based Agreements (VBAs)**: The company is extending its VBAs to ensure adherence and compliance, which is favorable for both patients and payers [60][61]

First Quarter 2025 This document contains "forward looking statements"—that is, statements related to future, not past, events—as defined in Section 21E of the Securities Exchange Act of 1934, as amended, that reflect our current expectations regarding our future growth, results of operations, financial condition, cash flows, performance, business prospects and opportunities, as well as assumptions made by, and information currently available to, our management. We have tried to identify forward looking sta ...

Sunrun Inc. RUN shares are trading higher on Thursday after the company reported better-than-expected first-quarter results on Wednesday.The company reported an EPS of 20 cents per share, which beat the analyst consensus estimate of 25 cents loss and revenue of $504.27 million, which beat the consensus estimate of $484.06 million.Guggenheim analyst Joseph Osha kept Neutral rating on the stock and writes that while overall customer volume growth is modest in the quarter (additions of 25,428, up only 6%, with ...

Financial Data and Key Metrics Changes - The company reported first quarter 2025 earnings of $2.27 per share, reflecting a $0.30 increase compared to the first quarter of 2024 [4][16] - The earnings guidance for 2025 is reaffirmed at $5.17 to $5.27 per share, assuming normal weather conditions for the remainder of the year [5][22] - The long-term compound annual growth rate (CAGR) target remains at 6.5% to 7% [5][22] Business Line Data and Key Metrics Changes - Utility operations earnings increased by $0.28 compared to the first quarter of 2024, driven by weather impacts and rate-based growth [16][17] - Earnings from the Energy Infrastructure segment increased by $0.05, largely due to higher production tax credits [20] - Earnings from the Corporate and Other segment decreased by $0.03, primarily due to higher interest expenses [21] Market Data and Key Metrics Changes - Wisconsin's unemployment rate stands at 3.2%, below the national average, indicating strong economic conditions [5] - Weather-normalized retail electric delivery saw a 0.7% growth, led by large commercial and industrial classes [18][20] - The company anticipates a weather-normal annual electric sales growth of 4.5% to 5% starting in 2027 [20] Company Strategy and Development Direction - The company is focused on a $28 billion capital investment plan aimed at economic growth and reliability [8][10] - A new Very Large Customer (VLC) tariff proposal has been filed to accommodate economic growth and attract data center investments [12][13] - The company is actively working on transitioning its generation assets to gas and renewables to meet future capacity needs [29][68] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the economic development along the I-94 corridor and ongoing projects, including significant expansions by companies like Microsoft and Eli Lilly [6][7][92] - The management is cautiously optimistic about the future, noting that while there is caution among customers regarding tariffs, significant projects are still progressing [91][92] - The company is monitoring federal developments related to the Inflation Reduction Act and is actively seeking to safe harbor projects in its capital plan [10][51] Other Important Information - The company has no active rate cases currently and is preparing for future rate case filings [12][15] - The company plans to raise a total of $700 to $800 million in common equity in 2025 through various programs [21][43] - The company is managing tariff impacts on its capital plan, estimating a 2% to 3% overall exposure [8][80] Q&A Session Summary Question: Thoughts on recent MISO capacity auction results and CapEx for data centers - Management indicated a tight auction and is working to ensure enough capacity to meet demand, with plans for additional gas generation [27][28] Question: Pipeline safety modernization program in Illinois and CapEx opportunities - Management expects to ramp up the program in 2026 and 2027, with spending projected to exceed $500 million annually [35][37] Question: Update on Microsoft and data center developments - Management confirmed ongoing strong demand and development from Microsoft, with no concerns about the project's progress [39][41] Question: Impact of tariffs on capital plan - Management noted that tariffs could impact costs, particularly for solar and battery projects, and will notify regulators of any significant increases [78][81] Question: Future of gas in Illinois and potential impacts from workshops - Management remains optimistic about the gas needs and the approved pipe replacement program, with no expected negative changes [96] Question: Commentary on large load customers outside data centers - Management reported cautious optimism among large customers, with ongoing expansions in various sectors despite tariff concerns [91][92]